PR Newswire
21 Jun 2022, 21:59 GMT+10
GAITHERSBURG, Md. and SUZHOU, China, June 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer, Dmitry Samarsky, PhD, will present the latest developments and expanded applications of its Dual-Targeted RNAi therapeutics based on its proprietary GalAhead technology and product pipeline, at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium. The Symposium will take place virtually on June 22-24, 2022.
Sirnaomics' proprietary GalNAc-RNAi therapeutic platform, GalAhead, relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA (miniaturized RNAi triggers) and muRNA (multi-unit RNAi triggers). mxRNAs are comprised of single ~30 nt long oligonucleotides to downregulate individual genes, while muRNA molecules are comprised of multiple oligonucleotides to silence two or more targets simultaneously. Sirnaomics will present data at the Symposium evaluating these two technologies, especially the muRNA molecule that has been validated in an animal model for its dual-targeted gene silencing activity, and a progress report on the quickly expanding GalAhead therapeutic pipeline.
Presentation Details
"Sirnaomics is striving to develop RNAi delivery technology for effective therapeutic application. Our novel GalAhead technology has been repeatedly validated with both single-targeted and dual-targeted RNAi therapeutics using rodents and non-human primate animal models," said Dr. Patrick Lu, founder, chairman of the Board, Executive Director, President and CEO of Sirnaomics. "We are expecting expanded clinical testing for our GalAhead platform and RNAi drug candidates for several liver metabolic diseases in 2023."
"Since we introduced GalAhead in 2019, the technology has continuously proved to be both robust and reproducible," said Dmitry Samarsky, PhD, Chief Technology Officer of Sirnaomics. "Based on this progress, we will have our first therapeutic candidate filed for IND approval by the end of 2022. This year, we have already nominated four more GalAhead based developmental candidates, including the first double-targeting molecule, and are planning to add more by the end of the year."
For more information about Sirnaomics' presentation, please visit the event website at https://www.umassmed.edu/RNATx/.
About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP705. Learn more at www.sirnaomics.com.
CONTACT:
Dmitry Samarsky, PhD
Chief Technology Officer, Sirnaomics
Email: [email protected]
Investor Relations:
Nigel Yip
Chief Financial Officer, China, Sirnaomics
Email: [email protected]
US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: [email protected]
Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: [email protected]
SOURCE Sirnaomics Ltd.
Get a daily dose of Singapore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.
More InformationWASHINGTON, DC - U.S. President Donald Trump on Monday said he believed God was behind his election loss in 2020, even though he has...
NEW YORK CITY, New York: Passenger numbers at Newark Liberty International Airport in New Jersey have dropped sharply, according to...
BRUSSELS, Belgium: European Union antitrust regulators are examining fees imposed by payment giants Visa and Mastercard, Bloomberg...
WASHINGTON, D.C.: The U.S. Army plans to change the records of transgender soldiers to list only their sex at birth, according to a...
WASHINGTON, D.C.: The Federal Aviation Administration (FAA) said this week that it will require airlines to reduce the number of flights...
GAZA - The home of a doctor working in the emergency room at the Nasser Medical Complex in southern Gaza was struck by Israel Air...
WASHINGTON, D.C.: New single-family home sales in the U.S. rose sharply in April to their highest level in over three years as builders...
VEVEY, Switzerland: Nestle is realigning its focus on its core food and beverage operations after expanding into areas like health...
DEARBORN, Michigan: Ford Motor Company has filed a lawsuit against several California lawyers and law firms, accusing them of cheating...
BRUSSELS, Belgium: U.S. drugmakers are charging significantly more for new treatments, particularly those targeting rare diseases,...
MINNETONKA, Minnesota: UnitedHealth shares took a sharp hit this week, after a report by the UK's Guardian alleged the healthcare giant...
HUNG YEN, Vietnam: A new US$1.5 billion luxury golf and residential project backed by the Trump Organization officially broke ground...